Johnson & Johnson (JNJ)
275.23
-3.20
(-1.15%)
USD |
NYSE |
Sep 04, 16:00
275.85
+0.62
(+0.23%)
Pre-Market: 20:00
Johnson & Johnson Research and Development Expense (Quarterly) : 3.603B for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 3.603B |
| March 31, 2026 | 3.495B |
| December 31, 2025 | 4.268B |
| September 30, 2025 | 3.693B |
| June 30, 2025 | 3.532B |
| March 31, 2025 | 3.226B |
| December 31, 2024 | 5.319B |
| September 30, 2024 | 4.952B |
| June 30, 2024 | 3.448B |
| March 31, 2024 | 3.546B |
| December 31, 2023 | 4.473B |
| September 30, 2023 | 3.442B |
| June 30, 2023 | 3.691B |
| March 31, 2023 | 3.442B |
| December 31, 2022 | 3.741B |
| September 30, 2022 | 3.538B |
| June 30, 2022 | 3.745B |
| March 31, 2022 | 3.485B |
| December 31, 2021 | 4.749B |
| September 30, 2021 | 3.43B |
| June 30, 2021 | 3.29B |
| March 31, 2021 | 3.065B |
| December 31, 2020 | 4.016B |
| September 30, 2020 | 2.827B |
| June 30, 2020 | 2.709B |
| Date | Value |
|---|---|
| March 31, 2020 | 2.47B |
| December 31, 2019 | 1.319B |
| September 30, 2019 | 4.51B |
| June 30, 2019 | 2.63B |
| March 31, 2019 | 2.997B |
| December 31, 2018 | 3.246B |
| September 30, 2018 | 2.518B |
| June 30, 2018 | 2.625B |
| March 31, 2018 | 2.166B |
| December 31, 2017 | 3.609B |
| September 30, 2017 | 2.555B |
| June 30, 2017 | 2.297B |
| March 31, 2017 | 1.958B |
| December 31, 2016 | 2.648B |
| September 30, 2016 | 2.176B |
| June 30, 2016 | 2.263B |
| March 31, 2016 | 1.918B |
| December 31, 2015 | 2.872B |
| September 30, 2015 | 2.161B |
| June 30, 2015 | 2.136B |
| March 31, 2015 | 1.883B |
| December 31, 2014 | 2.647B |
| September 30, 2014 | 2.031B |
| June 30, 2014 | 1.987B |
| March 31, 2014 | 1.836B |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Eli Lilly & Co. | 3.819B |
| Merck & Co., Inc. | 9.229B |
| Pfizer Inc. | 2.746B |
| Bristol Myers Squibb Co. | 2.316B |
| Liquidia Corp. | 16.88M |